Meridian Bioscience (VIVO) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts VIVO Hot Sheet
Price: $1.52 -5%
Financial Fact:
DILUTED EARNINGS PER COMMON SHARE: 0.13
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
DILUTED EARNINGS PER COMMON SHARE: 0.13
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Meridian Bioscience (NASDAQ: VIVO) reported Q4 EPS of $0.13, $0.02 worse than the analyst estimate of $0.15. Revenue for the quarter came in at $49 million versus the consensus estimate of $48.05 million.
For earnings history and earnings-related data on Meridian Bioscience (VIVO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- CrossAmerica Partners (CAPL) Misses Q3 EPS by 8c
- Enact Holdings (ACT) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
